New drug combo targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase trial tests a new drug called Sapu003, given with or without exemestane, in adults with advanced cancers that respond to mTOR pathways—including certain breast, kidney, liver, and neuroendocrine tumors. The main goal is to find the safest dose and check for side …
Phase: PHASE1 • Sponsor: SAPU NANO (US) LLC • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC